Clinical trial · Observational
Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation
NCT03490461CI-TRIAL-00032393completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Statin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Statin group
- description
- Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
- interventionNames
- Drug: Statin
- label
- Non-statin group
- description
- the administration of statins for less than 30 days after liver transplantation
Primary outcomes (1)
- measure
- A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.
- timeFrame
- up to December, 2017
- description
- Usually, liver CT is performed at 1 week, 1 month, 6 months, and every year until 5 years after surgery. Afterwards, liver CT is performed at 2-year intervals. Measurement of blood tumor markers \[AFP and prothrombin induced by vitamin K absence-II\] is performed every month for 6 months after discharge from the hospital and every 3 months thereafter. Additional liver CT, liver magnetic resonance imaging, or positron emission tomography-CT is performed when elevated tumor markers or suspicious lesions were noted. A new lesion with radiographic features compatible with HCC is defined as recurrence of HCC based on the reports of specialist in radiology.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who received LT at the Severance Hospital from 2006 to 2016. Exclusion Criteria: * early postoperative mortality (defined as death within 2 months after LT without signs of tumor recurrence) * patient with distant lymph node metastasis confirmed within 1 month after LT * Patients younger than 20 years of age * patients who had LT for cirrhosis without confirmed HCC
References
Publications (0)
Data not yet available
No reference posted for this study.